Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
LSTA
Lisata Therapeutics, Inc.
CAPPED RATING
Lisata Therapeutics, Inc. (LSTA) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.1
/ 5.0
C-
Value
C-
Factor Score
2.1
/ 5.0
Growth
D+
Factor Score
1.7
/ 5.0
Profitability
D+
Factor Score
1.8
/ 5.0
Momentum
C-
Factor Score
2.1
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-1.1
EV / EBITDA
-0.1
Rev Growth YoY
N/A
Gross Margin
N/M
Price Return 3M
17.4%
Price Return 12M
-39.0%
Catalyst Signal
0.00
Market Cap
$13.8M
TTM Revenue
$100.0K
Price / Sales
138.3
ROE
-101.7%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C- (2.1) | D+ (1.7) | D+ (1.8) | C- (2.1) | C+ (2.6) | C- (2.1) |
| 2026-11-06 | B- (3.1) | D+ (1.7) | C- (1.9) | C- (1.9) | C+ (2.7) | C (2.2) |
| 2026-10-30 | B- (3.0) | D+ (1.6) | C- (1.9) | C- (2.0) | C+ (2.7) | C (2.2) |
| 2026-10-23 | B- (3.0) | D+ (1.6) | D+ (1.8) | D (1.2) | C+ (2.6) | C- (2.1) |
| 2026-10-16 | B- (3.0) | D+ (1.6) | D+ (1.8) | D- (0.8) | C+ (2.6) | C- (2.0) |
Page
1
of
4